Small molecule
A small molecule is a relatively low-molecular-mass chemical compound, distinguished from larger biological agents such as proteins, antibodies, and nucleic-acid therapeutics.
A small molecule is a relatively low-molecular-mass chemical compound, distinguished from larger biological agents such as proteins, antibodies, and nucleic-acid therapeutics. In biomedical research, the term generally refers to chemically defined compounds that can be evaluated as drugs, pharmacological probes, inhibitors, activators, or molecular sensors. Small molecules may act by binding to proteins, ribonucleic acid (RNA), or other cellular components and thereby changing biochemical activity, molecular recognition, or downstream signaling.
Their pharmaceutical importance arises from the ability to design and optimize chemical structures for target binding, cellular activity, absorption, distribution, metabolism, and excretion. In drug discovery, approaches including molecular docking, molecular dynamics simulation, binding-free-energy calculation, machine learning, artificial intelligence, and molecular generative modeling are used to identify or refine compounds with desired properties. The recent literature represented here applies small molecules across antibacterial and antiviral research, RNA-targeted therapeutics, pharmacokinetic modeling, biomarker detection, rare-disease treatment, and computational chemistry.
Rebuilt from PubMed 18 Sept 2026 · no new papers today
Where the papers sit
16 papers study small molecule directly. Those 16 are one subject: Molecular Ligand Discovery. Computational screening, structure-guided design and phenotypic testing recur in efforts to find inhibitors, agonists and diagnostic probes. The work remains exploratory, spanning cancer, infection and viral targets without a shared therapeutic direction. No way of splitting those 16 scores better than chance. 2 new directions follow.
Small molecules are used to disarm pathogens rather than kill them or inhibit an essential bacterial process
The uropathogenic Escherichia coli Cpx26 study treated the small molecule as an antivirulence agent rather than a conventional bactericide: Cpx26 inhibited motility, biofilm formation, and bladder-cell adhesion at concentrations more than 60-fold below its MIC, and enhanced the activity of trimethoprim/sulfamethoxazole and fosfomycin. This assigns the compound a distinct role as a sublethal virulence-suppression adjunct for urinary tract infection, rather than as a molecule whose primary purpose is to eliminate bacteria directly 42725978Sep.
A small molecule is used as the recognition input that gates a CRISPR diagnostic signal rather than as a therapeutic effector
The antibiotic-detection lock-and-key aptamer–CRISPR/Cas12a study used antibiotic binding to disrupt an aptamer-maintained stem loop, thereby preventing activator generation and suppressing Cas12a trans-cleavage. The small molecule consequently functions as the analyte that controls a programmable signal-off sensor, extending its role beyond the therapeutic inhibitors, agonists, and drug-delivery agents represented elsewhere in the set 42626870Aug.
Recent Findings on small molecule
Broad Chemical Biology: Small-molecule discovery increasingly combines virtual screening, molecular docking, molecular dynamics simulations, deep learning, and generative models with biochemical, cellular, and in vivo validation 42734561Sep42665558Aug42413396Jul42317170Jun42296352Jun. Validated candidates span multidrug-resistant breast cancer, urinary tract infection, SARS-CoV-2, inflammatory disease, obesity, and biomarker detection, with compounds acting through transporter inhibition, antivirulence, receptor antagonism, protease inhibition, and signal amplification 42734561Sep42725978Sep42725964Sep42308788Jun42424921Jul41854094Mar. Computational binding predictions do not translate uniformly across compounds: Fumiquinazoline D disrupted the Skp2-Cks1 interaction, whereas related molecules stabilized it, and TLR2 antagonist B1 showed sub-micromolar inhibition but limited oral absorption 42665558Aug42308788Jun. Other candidates achieved direct target engagement, autophagy modulation, radiosensitization, or xenograft tumor suppression, while prodrug safety and pharmacokinetic advantages remain hypotheses requiring in vivo validation 42385395Jul42447749Jul42424921Jul. Development is moving toward site-aware RNA-ligand modeling, scalable absolute free-energy prediction, mechanistic subcutaneous absorption models, programmable sensing platforms, and small molecules that complement gene- and RNA-directed therapies 42720476Sep42296352Jun42348273Jun42626870Aug41996006Apr41864145Mar.
Written from 16 PubMed abstracts, each one cited by PMID above. Published: 2026-09-13. Last written: 2026-09-16 by GPT. Drafted by language models from published abstracts; not medical advice.